Mehrzadi Saeed, Tavakolifar Bahreh, Huseini Hasan Fallah, Mosavat Seyed Hamdollah, Heydari Mojtaba
1 Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
2 Alborz University of Medical Sciences, Karaj, Alborz, Iran.
J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18772728. doi: 10.1177/2515690X18772728.
Regarding preclinical evidence for antidiabetic effects of Boswellia serrata, we evaluated antihyperglycemic and lipid-lowering effects of Boswellia serrata gum resin in type 2 diabetic patients. Fifty-six diabetic patients were randomly allocated to 2 groups to receive 250 mg of the Boswellia serrata gum resin or placebo twice daily for 8 weeks in addition to their routine antidiabetic treatments. Although there was a considerable reduction after the intervention in the field of fasting blood sugar, glycosylated hemoglobin, and triglyceride in the Boswellia serrata gum resin group, no significant difference was observed in all outcome measures between the 2 groups at the end of the study. The current study showed that 8 weeks of complementary use of Boswellia serrata gum resin with a daily dose of 500 mg had no better glucose and lipid-lowering effect than placebo in diabetic patients.
关于锯叶乳香抗糖尿病作用的临床前证据，我们评估了锯叶乳香树胶树脂对2型糖尿病患者的降血糖和降脂作用。56名糖尿病患者被随机分为2组，除常规抗糖尿病治疗外，每天两次接受250毫克锯叶乳香树胶树脂或安慰剂治疗，持续8周。尽管锯叶乳香树胶树脂组干预后空腹血糖、糖化血红蛋白和甘油三酯水平有显著降低，但研究结束时两组在所有结局指标上均未观察到显著差异。目前的研究表明，糖尿病患者每天补充500毫克锯叶乳香树胶树脂8周，其降血糖和降脂效果并不比安慰剂更好。
